Small bowel involvement is a prognostic factor in colorectal carcinomatosis treated with complete cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy

World Journal of Surgical Oncology

Jean-Marc Bereder¹  Daniel Benchimol¹  Amine Rahili¹  Jean-Louis Bernard¹  Emmanuel I Benizri¹ 

[1] Department of General Surgery and Digestive Cancerology, Centre Hospitalier Universitaire de Nice, Hôpital Archet 2, 151 Route de Saint Antoine de Ginestière, Nice Cedex 3 B.P. 3079, France

关键词: Intraperitoneal chemotherapy;    Cytoreductive surgery;    Prognostic factors;    Peritoneal carcinomatosis;    Colorectal cancer;   

Others  :  827892
DOI  :  10.1186/1477-7819-10-56

 received in 2012-01-01, accepted in 2012-04-11,  发布年份 2012

【 摘 要 】

Background

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) is a promising treatment for patients with peritoneal carcinomatosis (PC). Our objective was to identify new prognostic factors in patients with PC from colorectal cancer treated with this procedure.

Methods

All patients with PC from colorectal cancer treated by HIPEC from January 2000 to December 2007 were prospectively included. The tumor extension was assessed by the Peritoneal Cancer Index (PCI) and the residual disease was recorded using the completeness cytoreductive score (CCs). All clinical and treatment data were computed in univariate and multivariable analyses using survival as primary end point.

Results

We carried out 51 complete procedures in 49 consecutive patients. The mean PCI was 10. The allocation of CCs was: CC-0 = 37, CC-1 = 14. The five-year overall and progression-free survival rate were 40% and 20%, respectively. Several prognostic factors for survival were identified by univariate analysis: PCI < 9 (P < 0.001), CC-0 vs. CC-1 (P < 0.01) and involvement of area 4 (P = 0.06), area 5 (P = 0.031), area 7 (P = 0.014), area 8 (P = 0.022), area 10 (P < 0.0001), and area 11 (P = 0.02). Only the involvement of the distal jejunum (area 10) was significant in the multivariable analysis (P = 0.027).

Conclusions

We demonstrated that the involvement of area 10 (distal jejunum of the PCI score) was an independent factor associated with poor prognosis.

【 授权许可】

   
2012 Benizri et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Glehen O, Osinsky D, Beaujard AC, Gilly FN: Natural history of peritoneal carcinomatosis from non-gynecologic malignancies. Surg Oncol Clin N Am 2003, 12:729-739.
• [2]Sadeghi B, Arvieux C, Glehen O, Beaujard AC, Rivoire M, Baulieux J, Fontaumard E, Brachet A, Caillot JL, Faure JL, Porcheron J, Peix JL, François Y, Vignal J, Gilly FN: Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer 2000, 88:358-363.
• [3]Sugarbaker PH, Gianola FJ, Speyer JC, Wesley R, Barofsky I, Meyers CE: Prospective, randomized trial of intravenous versus intraperitoneal 5-fluorouracil in patients with advanced primary colon or rectal cancer. Surgery 1985, 98:414-422.
• [4]Glehen O, Cotte E, Schreiber V, Sayag-Beaujard AC, Vignal J, Gilly FN: Intraperitoneal chemohyperthermia and attempted cytoreductive surgery in patients with peritoneal carcinomatosis of colorectal origin. Br J Surg 2004, 91:747-754.
• [5]Glehen O, Kwiatkowski F, Sugarbaker PH, Elias D, Levine EA, De Simone M, Barone R, Yonemura Y, Cavaliere F, Quenet F, Gutman M, Tentes AA, Lorimier G, Bernard JL, Bereder JM, Porcheron J, Gomez-Portilla A, Shen P, Deraco M, Rat P: Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol 2004, 22:3284-3292.
• [6]Shen P, Hawksworth J, Lovato J, Loggie BW, Geisinger KR, Fleming RA, Levine EA: Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy with mitomycin C for peritoneal carcinomatosis from nonappendiceal colorectal carcinoma. Ann Surg Oncol 2004, 11:178-186.
• [7]Sugarbaker PH, Schellinx ME, Chang D, Koslowe P, von Meyerfeldt M: Peritoneal carcinomatosis from adenocarcinoma of the colon. World J Surg 1996, 20:585-591.
• [8]Elias D, Lefevre JH, Chevalier J, Brouquet A, Marchal F, Classe JM, Ferron G, Guilloit JM, Meeus P, Goéré D, Bonastre J: Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol 2009, 27:681-685.
• [9]Verwaal VJ, van Ruth S, de Bree E, van Sloothen GW, van Tinteren H, Boot H, Zoetmulder FA: Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 2003, 21:3737-3743.
• [10]Glehen O, Mohamed F, Gilly FN: Peritoneal carcinomatosis from digestive tract cancer: new management by cytoreductive surgery and intraperitoneal chemohyperthermia. Lancet Oncol 2004, 5:219-228.
• [11]Sugarbaker PH, Averbach AM, Jacquet P, Stuart OA, Stephens AD: Hyperthermic intraoperative intreperitoneal chemotherapy (HIIC) with mitomycin C. Surg Technol Int 1996, 5:245-249.
• [12]Elias D, Antoun S, Goharin A, Otmany AE, Puizillout JM, Lasser P: Research on the best chemohyperthermia technique of treatment of peritoneal carcinomatosis after complete resection. Int J Surg Investig 2000, 1:431-439.
• [13]Beaujard AC, Glehen O, Caillot JL, Francois Y, Bienvenu J, Panteix G, Garbit F, Grandclément E, Vignal J, Gilly FN: Intraperitoneal chemohyperthermia with mitomycin C for digestive tract cancer patients with peritoneal carcinomatosis. Cancer 2000, 88:2512-2519.
• [14]Verwaal VJ, Boot H, Aleman BM, van Tinteren H, Zoetmulder FA: Recurrences after peritoneal carcinomatosis of colorectal origin treated by cytoreduction and hyperthermic intraperitoneal chemotherapy: location, treatment, and outcome. Ann Surg Oncol 2004, 11:375-379.
• [15]da Silva RG, Sugarbaker PH: Analysis of prognostic factors in seventy patients having a complete cytoreduction plus perioperative intraperitoneal chemotherapy for carcinomatosis from colorectal cancer. J Am Coll Surg 2006, 203:878-886.
• [16]Yan TD, Morris DL: Cytoreductive surgery and perioperative intraperitoneal chemotherapy for isolated colorectal peritoneal carcinomatosis: experimental therapy or standard of care? Ann Surg 2008, 248:829-835.
• [17]Elias D, Blot F, El Otmany A, Antoun S, Lasser P, Boige V, Rougier P, Ducreux M: Curative treatment of peritoneal carcinomatosis arising from colorectal cancer by complete resection and intraperitoneal chemotherapy. Cancer 2001, 92:71-76.
• [18]Elias D, Benizri E, Vernerey D, Eldweny H, Dipietrantonio D, Pocard M: Preoperative criteria of incomplete resectability of peritoneal carcinomatosis from non-appendiceal colorectal carcinoma. Gastroenterol Clin Biol 2005, 29:1010-1013.
• [19]Esquivel J, Chua TC, Stojadinovic A, Melero JT, Levine EA, Gutman N, Howard R, Piso P, Nissan A, Gomez-Portilla A, Gonzalez-Bavon L, Gonzalez-Moreno S, Shen P, Stewart JH, Sugarbaker PH, Barone RM, Hoefer R, Morris DL, Sardi A, Sticca RP: Accuracy and clinical relevance of computed tomography scan interpretation of peritoneal cancer index in colorectal cancer peritoneal carcinomatosis: a multi-institutional study. J Surg Oncol 2010, 102:565-570.
• [20]Yan TD, Sim J, Morris DL: Selection of patients with colorectal peritoneal carcinomatosis for cytoreductive surgery and peritoperative intraperitoneal chemotherapy. Ann Surg Oncol 2007, 14:1807-1817.
• [21]Michailova K, Wassilev W, Wedel T: Scanning and transmission electron microscopic study of visceral and parietal peritoneal regions in the rat. Ann Anat 1999, 181:253-260.
• [22]Berndt WO, Gosselon RE: Differential changes in permeability of mesentery to rubidium and phosphate. Am J Physiol 1962, 202:761-767.
• [23]Glehen O, Gilly FN, Boutitie F, Bereder JM, Quenet F, Sideris L, Mansvelt B, Lorimier G, Msika S, Elias D, French Surgical Association: Toward curative treatment of peritoneal carcinomatosis from non ovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy: a multi-institutional study of 1290 patients. Cancer 2010, 116:5608-5618.